<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03266302</url>
  </required_header>
  <id_info>
    <org_study_id>ZKSJ0108</org_study_id>
    <nct_id>NCT03266302</nct_id>
  </id_info>
  <brief_title>Hemoadsorption for Prevention of Vasodilatory Shock in Cardiac Surgery Patients With Infective Endocarditis</brief_title>
  <acronym>REMOVE</acronym>
  <official_title>Revealing Mechanisms and Investigating Efficacy of Hemoadsorption for Prevention of Vasodilatory Shock in Cardiac Surgery Patients With Infective Endocarditis - a Multicentric Randomized Controlled Group Sequential Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jena University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CytoSorbents, Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>B.R.A.H.M.S. (part of ThermoFisher Scientific)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fraunhofer Institute for Interfacial Engineering and Biotechnology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>German Federal Ministry of Education and Research (BMBF)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Jena University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Infective endocarditis (IE) is associated with high hospital mortality for various reasons;
      one of them is circulatory failure in patients who undergo cardiac surgery for IE. One
      discussed reason underlying circulatory failure during surgery is the release of
      vasodilatatory mediators and cytokines. This study examines the efficacy and safety of a
      hemoadsorption filter which is approved for the reduction of the concentration of cytokines
      in the bloodstream.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators assume a common standard deviation of 3.8 points and that a 1.4-point lower
      SOFA score in the Intervention Group is of clinical relevance.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 17, 2018</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>two-arm randomized-controlled group sequential (Pocock) design for assessing superiority and safety</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Participant will not be informed about group allocation</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>SOFA Score</measure>
    <time_frame>24 hours before until day 9 post-surgery</time_frame>
    <description>The investigators will test if mean SOFA scores are different for the experimental and control group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall mortality rate</measure>
    <time_frame>until day 30 post surgery</time_frame>
    <description>Overall mortality rate until day 30 post-surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in cytokine and cfDNA levels</measure>
    <time_frame>24 hours before, during cardiac surgery and 24 hours after surgery</time_frame>
    <description>changes in cytokine and cfDNA levels will be measured at different time points before, during and after surgery in both groups; only for the first 2x25 patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SOFA subscores</measure>
    <time_frame>24 hours before surgery until day 9 post-surgery</time_frame>
    <description>single SOFA subscores will be analyzed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days on ventilator, vasopressor and renal replacement therapy</measure>
    <time_frame>until day 30 post-surgery</time_frame>
    <description>Total days on ventilator, vasopressor and renal replacement therapy within 30 days post-surgery will be assessed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of stroke</measure>
    <time_frame>until day 30 post-surgery</time_frame>
    <description>incidence of stroke within 30 days post-surgery will be assessed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>length of ICU and in-hospital stay</measure>
    <time_frame>until day 30 post-surgery</time_frame>
    <description>total length of ICU and in-hospital stay until day 30 post-surgery</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Infective Endocarditis</condition>
  <arm_group>
    <arm_group_label>Interventional group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Use of hemoadsorber for removal of cytokines. Participants undergoing cardiac surgery due to infective endocarditis will be treated using a hemoadsorption device (CytoSorb) within the cardiopulmonary Bypass circuit (=Intervention)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants undergoing cardiac surgery due to infective endocarditis will be treated according to Standard of care (no hemoadsorption advice installed in the CPB circuit)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>hemoadsorber for removal of cytokines</intervention_name>
    <description>Use of the hemoadsorber during cardiac surgery with CPB. Hemoadsorber is integrated into the CPB circuit according to manufacturer's recommendation.</description>
    <arm_group_label>Interventional group</arm_group_label>
    <other_name>CytoSorb(R)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with infective endocarditis (according to DUKE criteria) undergoing cardiac
             surgery

          -  informed consent

          -  age ≥18 years and ≤80 years

        Exclusion Criteria:

          -  EuroScoreII ≤ 3

          -  current participation in another interventional Trial

          -  pregnancy

          -  current immunosuppressive or immunomodulatory therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mahmoud Diab, Dr.</last_name>
    <role>Study Director</role>
    <affiliation>Jena University Hospital, Department of Cardiac and Thoracic Surgery</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stephanie Platzer, Dr.</last_name>
    <phone>+49 3641</phone>
    <phone_ext>9396696</phone_ext>
    <email>stephanie.platzer@med.uni-jena.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Frank M Brunkhorst, Prof. Dr.</last_name>
    <phone>+49 3641</phone>
    <phone_ext>9323381</phone_ext>
    <email>Frank.Brunkhorst@med.uni-jena.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Jena University Hospital, Dept. of Cardiac and Thoracic Surgery</name>
      <address>
        <city>Jena</city>
        <state>Thuringia</state>
        <zip>07747</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mahmoud Diab, Dr. med.</last_name>
      <phone>+49 3641</phone>
      <phone_ext>322978</phone_ext>
      <email>mahmoud.diab@med.uni-jena.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Bernardi MH, Rinoesl H, Dragosits K, Ristl R, Hoffelner F, Opfermann P, Lamm C, Preißing F, Wiedemann D, Hiesmayr MJ, Spittler A. Effect of hemoadsorption during cardiopulmonary bypass surgery - a blinded, randomized, controlled pilot study using a novel adsorbent. Crit Care. 2016 Apr 9;20:96. doi: 10.1186/s13054-016-1270-0.</citation>
    <PMID>27059056</PMID>
  </reference>
  <reference>
    <citation>Brunkhorst FM, Oppert M, Marx G, Bloos F, Ludewig K, Putensen C, Nierhaus A, Jaschinski U, Meier-Hellmann A, Weyland A, Gründling M, Moerer O, Riessen R, Seibel A, Ragaller M, Büchler MW, John S, Bach F, Spies C, Reill L, Fritz H, Kiehntopf M, Kuhnt E, Bogatsch H, Engel C, Loeffler M, Kollef MH, Reinhart K, Welte T; German Study Group Competence Network Sepsis (SepNet). Effect of empirical treatment with moxifloxacin and meropenem vs meropenem on sepsis-related organ dysfunction in patients with severe sepsis: a randomized trial. JAMA. 2012 Jun 13;307(22):2390-9. doi: 10.1001/jama.2012.5833.</citation>
    <PMID>22692171</PMID>
  </reference>
  <reference>
    <citation>Bustamante J, Arévalo A, Tamayo E, Sarria C, Aguilar-Blanco EM, Heredia M, Almansa R, Rico L, Iglesias V, Bermejo-Martin JF. Cytokine profiles linked to fatal outcome in infective prosthetic valve endocarditis. APMIS. 2014 Jun;122(6):526-9. doi: 10.1111/apm.12189. Epub 2013 Sep 30.</citation>
    <PMID>24106887</PMID>
  </reference>
  <reference>
    <citation>Boyle EM Jr, Pohlman TH, Johnson MC, Verrier ED. Endothelial cell injury in cardiovascular surgery: the systemic inflammatory response. Ann Thorac Surg. 1997 Jan;63(1):277-84. Review.</citation>
    <PMID>8993292</PMID>
  </reference>
  <reference>
    <citation>Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med. 2003 Jan 9;348(2):138-50. Review.</citation>
    <PMID>12519925</PMID>
  </reference>
  <reference>
    <citation>Minne L, Abu-Hanna A, de Jonge E. Evaluation of SOFA-based models for predicting mortality in the ICU: A systematic review. Crit Care. 2008;12(6):R161. doi: 10.1186/cc7160. Epub 2008 Dec 17. Review.</citation>
    <PMID>19091120</PMID>
  </reference>
  <reference>
    <citation>Prendergast BD, Tornos P. Surgery for infective endocarditis: who and when? Circulation. 2010 Mar 9;121(9):1141-52. doi: 10.1161/CIRCULATIONAHA.108.773598. Review.</citation>
    <PMID>20212293</PMID>
  </reference>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 28, 2017</study_first_submitted>
  <study_first_submitted_qc>August 29, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 30, 2017</study_first_posted>
  <last_update_submitted>January 18, 2018</last_update_submitted>
  <last_update_submitted_qc>January 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>vasodilatory shock</keyword>
  <keyword>hemoadsorption</keyword>
  <keyword>cardiac surgery</keyword>
  <keyword>cytokines</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endocarditis</mesh_term>
    <mesh_term>Endocarditis, Bacterial</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

